Olanzapine: a 5-year perspective

References

• Murray L. Physicians' Desk Reference. 6th Edition. Montvale, Thomson PDR, NY, USA (2006).
   Google Scholar
• Markowitz JS, Devane CL, Malcolm RJ et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J. Clin. Pharmacol.46(2), 164–171 (2006).
   PubMed Web of Science ®Google Scholar
• Tran PE, Bymaster FPE, Tye NE et al. In: Olanzapine (Zyprexa^®): A Novel Antipsychotic. Lippincott Williams and Wilkins Healthcare, PA, USA (2000).
   Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet.37(3), 177–193 (1999).
   PubMed Web of Science ®Google Scholar
• Kando JC, Shepski JC, Satterlee W et al. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann. Pharmacother.31(11), 1325–1334 (1997).
   Google Scholar
• Jann MW. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol. Bull.36(3), 22–41 (2002).
   PubMedGoogle Scholar
• Kassahun K, Mattiuz E, Nyhart E Jr. et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos.25(1), 81–93 (1997).
   PubMed Web of Science ®Google Scholar
• Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J. Psychiatry Neurosci.28(2), 99–112 (2003).
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Herraiz AG, Ramos SI et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol.23(2), 119–127 (2003).
   PubMed Web of Science ®Google Scholar
• Shirley KL, Hon YY, Penzak SR et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology28(5), 961–966 (2003).
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry158(7), 1149–1151 (2001).
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs19(2), 147–164 (2005).
   Google Scholar
• Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst. Rev. (2), CD003729 (2005).
   Google Scholar
• Mattiuz E, Franklin R, Gillespie T et al. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab. Dispos.25(5), 573–583 (1997).
   PubMed Web of Science ®Google Scholar
• Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet.38(5), 393–414 (2000).
   PubMed Web of Science ®Google Scholar
• Bymaster F, Perry KW, Nelson DL et al. Olanzapine: a basic science update. Br. J. Psychiatry37(Suppl.), 36–40 (1999).
   Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology14(2), 87–96 (1996).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry.7(Suppl. 1), S57–S63 (2002).
   Google Scholar
• Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, a1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.)124(1–2), 87–94 (1996).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Nelson DL, DeLapp NW et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro. Schizophr. Res.37(1), 107–122 (1999).
   PubMed Web of Science ®Google Scholar
• Ninan I, Kulkarni SK. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals. Psychopharmacology (Berl.)142(2), 175–181 (1999).
   Google Scholar
• Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology21(2 Suppl.), S106–S115 (1999).
   PubMed Web of Science ®Google Scholar
• Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol. Psychiatry47(11), 1000–1004 (2000).
   Google Scholar
• Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology28(1), 1–13 (2003).
   PubMed Web of Science ®Google Scholar
• Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse39(2), 152–160 (2001).
   Google Scholar
• Fatemi SH, Reutiman TJ, Folsom TD et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology (2006) (Epub ahead of print).
   Google Scholar
• Ugale RR, Hirani K, Morelli M, Chopde CT. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology29(9), 1597–1609 (2004).
   Google Scholar
• Freedman R. The choice of antipsychotic drugs for schizophrenia. N. Engl. J. Med.353(12), 1286–1288 (2005).
   Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr.9(10 Suppl. 11), 6–14 (2004).
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr., Sutton VK, Taylor CC et al. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J. Clin. Psychopharmacol.26(1), 40–44 (2006).
   Google Scholar
• Lambert M, Haro JM, Novick D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta. Psychiatr. Scand.111(3), 232–243 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert M, Holzbach R, Moritz S et al. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int. Clin. Psychopharmacol.18(5), 251–260 (2003).
   Google Scholar
• Moritz S, Woodward TS, Krausz M, Naber D. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int. Clin. Psychopharmacol.17(1), 41–44 (2002).
   PubMed Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert M et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res.50(1–2), 79–88 (2001).
   PubMed Web of Science ®Google Scholar
• Naber D, Riedel M, Klimke A et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta. Psychiatr. Scand.111(2), 106–115 (2005).
   PubMed Web of Science ®Google Scholar
• Wolf K, Mass R, Kiefer F et al. The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study. J. Clin. Psychopharmacol.25(3), 278–281 (2005).
   Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol.8(3), 457–472 (2005).
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl.)106(4), 433–438 (1992).
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am. J. Psychiatry154(6), 782–791 (1997).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Lee MA, Jayathilake K et al. Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed.6(2), 27 (2004).
   PubMedGoogle Scholar
• Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry57(3), 249–258 (2000).
   PubMed Web of Science ®Google Scholar
• Stip E, Chouinard S, Boulay LJ. On the trial of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry29(2), 219–232 (2005).
   PubMed Web of Science ®Google Scholar
• Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy24(12), 1759–1783 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs16(7), 457–471, (2002).
   PubMed Web of Science ®Google Scholar
• Dott SG, Weiden P, Hopwood P et al. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists. CNS Spectrums6(4), 333–338 (2001).
   PubMedGoogle Scholar
• Collaborative WorkingGroup on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J. Clin. Psychiatry59(Suppl. 12), 3–9 (1998).
   Google Scholar
• Cohen AS, Forbes CB, Mann MC, Blanchard JJ. Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. Schizophr. Res.81(2–3), 227–238 (2006).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry57(6), 688–691 (2005).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry161(6), 985–995 (2004).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Young CA, Rock SL et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr. Res.81(1), 1–15 (2006).
   PubMed Web of Science ®Google Scholar
• Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr. Bull.31(1), 167–174 (2005).
   PubMed Web of Science ®Google Scholar
• Laes JR, Sponheim SR. Does cognition predict community function only in schizophrenia? A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects. Schizophr. Res. (2006) (Epub ahead of print).
   Google Scholar
• Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J. Clin. Psychopharmacol.23(4), 342–348 (2003).
   PubMed Web of Science ®Google Scholar
• Hewitt J, Coffey M. Therapeutic working relationships with people with schizophrenia: literature review. J. Adv. Nurs.52(5), 561–570 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor M, Chaudhry I, Cross M et al. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum. Psychopharmacol.20(3), 175–181 (2005).
   PubMed Web of Science ®Google Scholar
• de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl.)175(3), 389–390 (2004).
   PubMedGoogle Scholar
• Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann. Med.38(1), 52–63 (2006).
   PubMed Web of Science ®Google Scholar
• Menza M, Vreeland B, Minsky S et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry65(4), 471–477 (2004).
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. NZJ Psychiatry39(6), 479–486 (2005).
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD et al. The effects of an educational intervention on antipsychotic-induced weight gain. J. Nurs. Scholarship35(3), 237–241 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27(2), 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Ader M, Kim SP, Catalano KJ et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes54(3), 862–871 (2005).
   PubMed Web of Science ®Google Scholar
• Dwyer DS, Lu XH, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res.971(1), 31–39 (2003).
   PubMed Web of Science ®Google Scholar
• Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J. Clin. Psychiatry65(4), 464–470 (2004).
   PubMed Web of Science ®Google Scholar
• Crow TJ, Cross AJ, Johnstone EC et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol.2(5), 336–340 (1982).
   Google Scholar
• Kinon BJ, Jeste DV, Kollack-Walker S et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog. Neuropsychopharmacol. Biol. Psychiatry28(6), 985–996 (2004).
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can. J. Psychiatry50(11), 703–714 (2005).
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry161(3), 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Beasley CM, Jr., Tollefson GD, Tran PV. Safety of olanzapine. J. Clin. Psychiatry58(Suppl. 10), 13–17 (1997).
   PubMed Web of Science ®Google Scholar
• Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr. Rev.24(1), 1–27 (2003).
   PubMed Web of Science ®Google Scholar
• Koren G, Cohn T, Chitayat D et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am. J. Psychiatry159(1), 136–137 (2002).
   PubMed Web of Science ®Google Scholar
• McKenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J. Clin. Psychiatry66(4), 444–449 (2005).
   PubMed Web of Science ®Google Scholar
• Antia SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J. Child. Adolesc. Psychopharmacol.15(6), 970–985 (2005).
   PubMed Web of Science ®Google Scholar
• Macias WL, Bergstrom RF, Cerimele BJ et al. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy18(6), 1237–1248 (1998).
   PubMedGoogle Scholar
• Rosaria Muscatello M, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia46(5), 771–774 (2005).
   PubMedGoogle Scholar
• Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin. Pharmacother.4(7), 1175–1183 (2003).
   PubMed Web of Science ®Google Scholar
• Albers LJ, Ozdemir V, Marder SR et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J. Clin. Psychopharmacol.25(2), 170–174 (2005).
   PubMed Web of Science ®Google Scholar
• de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berl.)155(2), 219–220 (2001).
   PubMed Web of Science ®Google Scholar
• Bajaj V, Comyn DJ. Norepinephrine in the treatment of olanzapine overdose. Anaesthesia57(10), 1040–1041 (2002).
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Hoffman L, Margolese HC. Seizures, coma, and coagulopathy following olanzapine overdose. Can. J. Psychiatry50(2), 126–127 (2005).
   PubMedGoogle Scholar
• Bosch RF, Baumbach A, Bitzer M, Erley CM. Intoxication with olanzapine. Am. J. Psychiatry157(2), 304–305 (2000).
   PubMed Web of Science ®Google Scholar
• Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J. Psychiatry Neurosci.28(4), 253–261 (2003).
   PubMed Web of Science ®Google Scholar
• Davis LE, Becher MW, Tlomak W et al. Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology. Am. J. Psychiatry162(1), 28–33 (2005).
   PubMed Web of Science ®Google Scholar
• Doucette DE, Grenier JP, Robertson PS. Olanzapine-induced acute pancreatitis. Ann. Pharmacother.34(10), 1128–1131 (2000).
   PubMed Web of Science ®Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J. Subst. Abuse Treat.21(4), 217–221 (2001).
   PubMed Web of Science ®Google Scholar
• Sayers SL, Campbell EC, Kondrich J et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J. Nerv. Ment. Dis.193(6), 379–386 (2005).
   PubMed Web of Science ®Google Scholar
• Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr. Bull.30(1), 3–20 (2004).
   PubMed Web of Science ®Google Scholar
• Grootens KP, Verkes RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry38(1), 20–23 (2005).
   Google Scholar
• Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr. Res.71(1), 97–101 (2004).
   PubMedGoogle Scholar
• Marazziti D, Pfanner C, Dell'Osso B et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J. Psychopharmacol.19(4), 392–394 (2005).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry62(4), 361–370 (2005).
   PubMed Web of Science ®Google Scholar